카나프테라퓨틱스

0082N0KOSDAQ

58.8 / 100

Reference Date: 2026-09-08

Financial Score20.5 / 40

News Sentiment21.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Slightly up 1.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Canapharmaceuticals is an innovative biopharmaceutical company developing novel drugs for oncology and ophthalmic diseases using human genome-based technology. The company has a diverse pipeline of seven projects, including bispecific antibodies, ADCs, and synthetic drugs, and has secured significant revenue through early-stage technology transfers and co-development partnerships with major pharmaceutical firms in South Korea.

Number of Employees

23people

Average Salary

55.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

15.40Industry Average 1.200.0Point

12.8x industry avg (risky)

ROE

—Industry Average 8.003.5Point

Debt Ratio

5.73Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
남들 투자 망설일때 과감한 베팅…'바이오 명가' 거듭난 프리미어 [대....
카나프테라퓨틱스는 바이오 분야 전문성 강화와 프리미어 인수 이후 영업이익이 크게 증가하며 긍정적인 시장 반응을 얻고 있다.
Positive
오스코텍 "항암제 내성, 초기 단계부터 막을 것"
O스코텍의 신약 후보물질 OCT-598이 초기 치료 단계부터 항암제 내성을 차단하는 혁신적인 접근법을 제시하여 카나프테라퓨틱스에 긍정적 영향을 미칠 것으로 예상됩니다.
Positive
[마켓인]아주IB, 상반기 영업이익 462억…역대 최대 실적에 '방긋'
아주IB투자의 역대 최대 영업이익 발표로 카나프테라퓨틱스 관련 투자 관심 증가 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 14,330Won52-week high 52,20052-week low 9,240

1-month return3.0Point

1m 1.42% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-12